Xeris Biopharma (XERS) Q2 2026 earnings review
Recorlev Powers Top-Line Growth While One-Time Charge Sinks Net Income
Xeris continues to execute on its primary growth engine, Recorlev, which surged 81% YoY and drove total revenue to $92.1M (+29% YoY). However, GAAP earnings experienced a violent reversing trend, swinging to a $31.1M Net Loss due to a $30.8M non-cash charge from extinguishing 2028 convertible notes. Beneath this accounting noise, operations remain healthy: Adjusted EBITDA expanded to $19.3M, and management tightened its FY26 revenue guidance upwards. Yet, a clear blemish remains as Gvoke revenue turned negative YoY, contradicting the company's narrative of 'solid' performance for the segment.
🐂 Bull Case
The early-2026 doubling of the commercial sales force is paying off. Recorlev generated $56.8M, up 81% YoY and accelerating sequentially from Q1's $49.8M.
By eliminating approximately $33.5M of its 2028 Convertible Notes through cash and equity exchanges, Xeris removed a looming debt overhang, freeing up future cash flows.
🐻 Bear Case
Once a stable foundation, Gvoke revenue is reversing into negative territory, shrinking 4% YoY. Medicare channel headwinds and payer resets appear to be causing lasting damage.
SG&A expenses surged 37% YoY to $61M. If Recorlev growth normalizes, this structurally higher cost base will compress operating leverage.
⚖️ Verdict: ⚪
Neutral. Top-line execution on Recorlev is stellar, and the guidance raise signals confidence. But a collapsing Gvoke growth rate and massively inflated SG&A costs suggest the core business is becoming dangerously concentrated on a single product's success.
Key Themes
Recorlev Adoption Fueling the Top Line
The Q1 expansion of the Recorlev commercial sales force (to roughly 80 reps) is demonstrably working. Revenue for the Cushing's syndrome therapy reached $56.8M, an 81% YoY increase. This represents an accelerating sequential trend ($49.8M in Q1) and validates management's aggressive investment strategy in patient acquisition.
Data Contradicts Narrative: Gvoke Contraction
Management stated in the press release that 'Gvoke delivered solid sequential improvement in line with our expectations.' While technically true sequentially ($22.5M vs $20.8M in Q1), this masks a reversing YoY trend: Gvoke shrank by 4% compared to Q2 2025 ($23.5M). Macro factors like Medicare resets were blamed last quarter, but this persistent weakness suggests structural competitive or payer headwinds.
Margin Expansion via Favorable Mix
Gross margins are showing a stable, upward trajectory, reaching 86% in Q2 (up from 82% a year ago). Because Recorlev commands a significantly higher margin than Gvoke, the rapid shift in product mix toward Recorlev structurally elevates the company's profitability profile at the gross level.
SG&A Expense Acceleration
Operating leverage took a hit as Selling, General and Administrative (SG&A) expenses accelerated by 37% YoY to $61M. While this was telegraphed as necessary to support the Recorlev sales force expansion, it outpaced total revenue growth (29%). Management must prove they can rein in these costs once the new reps are fully productive.
Innovation and IP Defense
Xeris fortified its defensive moat. The USPTO issued a Notice of Allowance for Keveyis, expected to extend IP protection through 2039. Simultaneously, they secured a second patent for XP-8121, their Phase 3-ready hypothyroidism asset. This significantly de-risks the long-term cash flow profile of their legacy and pipeline assets.
Debt Exchange Crushes GAAP Net Income
A reversing trend hit the bottom line, with Net Loss dropping to $31.1M from positive territory in prior quarters. This was driven entirely by a $31M one-time, non-cash charge to extinguish 2028 Convertible Notes. While this fundamentally improves the balance sheet long-term, investors should monitor for any future dilutive equity issuances tied to debt cleanups.
Other KPIs
Accelerating significantly from $12.5M a year ago. Stripping away the $31M debt extinguishment charge and $11.1M in share-based compensation, the core business generated solid cash earnings, validating the underlying profitability of the Recorlev scale-up.
Accelerating upward by 32% YoY ($8.1M in Q2 2025). This is explicitly tied to the preparations for the XP-8121 Phase 3 trial. As long as this asset remains the primary pipeline focus, R&D expenses will likely remain elevated.
Guidance
Accelerating upward from previous ranges. The company tightened the low end (previously $380M) based on Recorlev's outperformance. The $387.5M midpoint implies a robust ~33% YoY growth rate compared to FY25's $291.8M.
Key Questions
Gvoke Reversal
Despite sequential improvement, Gvoke contracted 4% YoY. Is this purely driven by Medicare pricing resets, or are you seeing volume loss to competitors like Baqsimi? What is the structural fix?
SG&A Normalization
SG&A grew 37% this quarter. As the Recorlev sales reps reach optimal productivity over the next 6 months, when should we expect SG&A growth to meaningfully decouple from revenue growth?
XP-8121 Gating Items
You received a new patent for XP-8121. What specific commercial formulation or device validation steps remain before the Phase 3 trial can officially dose its first patient?
Future Convertible Debt Plans
Following the $23M exchange of 2028 notes, what is the strategy for the remaining debt stack, and should investors model further non-cash extinguishment charges in H2 2026?